AIA Group Ltd Raises Position in Abbott Laboratories $ABT

AIA Group Ltd grew its holdings in shares of Abbott Laboratories (NYSE:ABT) by 51.5% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 103,474 shares of the healthcare product maker’s stock after acquiring an additional 35,180 shares during the period. AIA Group Ltd’s holdings in Abbott Laboratories were worth $13,859,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently bought and sold shares of ABT. State Street Corp lifted its position in shares of Abbott Laboratories by 0.9% during the 2nd quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock valued at $10,656,964,000 after buying an additional 689,517 shares in the last quarter. Capital International Investors increased its holdings in Abbott Laboratories by 2.5% in the 3rd quarter. Capital International Investors now owns 61,614,739 shares of the healthcare product maker’s stock worth $8,251,974,000 after acquiring an additional 1,478,076 shares in the last quarter. Norges Bank bought a new stake in Abbott Laboratories during the 2nd quarter worth approximately $3,026,180,000. Massachusetts Financial Services Co. MA lifted its holdings in Abbott Laboratories by 5.8% during the third quarter. Massachusetts Financial Services Co. MA now owns 15,096,907 shares of the healthcare product maker’s stock valued at $2,022,080,000 after purchasing an additional 821,325 shares in the last quarter. Finally, Invesco Ltd. lifted its holdings in Abbott Laboratories by 51.0% during the third quarter. Invesco Ltd. now owns 13,951,907 shares of the healthcare product maker’s stock valued at $1,868,718,000 after purchasing an additional 4,713,135 shares in the last quarter. 75.18% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ABT has been the subject of a number of analyst reports. Leerink Partners reduced their price objective on shares of Abbott Laboratories from $136.00 to $119.00 and set a “market perform” rating for the company in a research note on Friday, January 30th. Piper Sandler lowered their target price on shares of Abbott Laboratories from $150.00 to $135.00 and set an “overweight” rating on the stock in a research note on Friday, January 23rd. Sanford C. Bernstein cut their price target on Abbott Laboratories from $154.00 to $125.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Royal Bank Of Canada decreased their price target on Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating on the stock in a report on Friday, January 23rd. Finally, Raymond James Financial lowered their price objective on Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a research report on Friday, January 23rd. Two investment analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating and four have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $136.16.

Insider Activity at Abbott Laboratories

In other news, EVP Daniel Gesua Sive Salvadori sold 885 shares of the firm’s stock in a transaction dated Monday, March 2nd. The shares were sold at an average price of $115.58, for a total value of $102,288.30. Following the completion of the sale, the executive vice president owned 146,377 shares in the company, valued at approximately $16,918,253.66. This trade represents a 0.60% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Mary K. Moreland sold 613 shares of Abbott Laboratories stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $115.58, for a total transaction of $70,850.54. Following the transaction, the executive vice president directly owned 104,291 shares of the company’s stock, valued at approximately $12,053,953.78. This represents a 0.58% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,055 shares of company stock valued at $353,097 over the last three months. Corporate insiders own 0.46% of the company’s stock.

Abbott Laboratories Stock Performance

Abbott Laboratories stock opened at $108.41 on Thursday. The company’s 50-day moving average price is $113.54 and its 200-day moving average price is $123.39. The company has a quick ratio of 1.18, a current ratio of 1.58 and a debt-to-equity ratio of 0.19. The company has a market cap of $188.81 billion, a PE ratio of 29.14, a price-to-earnings-growth ratio of 1.76 and a beta of 0.74. Abbott Laboratories has a twelve month low of $105.27 and a twelve month high of $139.06.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 EPS for the quarter, meeting analysts’ consensus estimates of $1.50. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.73%. The firm had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. During the same quarter last year, the firm earned $1.34 EPS. The firm’s revenue for the quarter was up 4.4% compared to the same quarter last year. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. On average, equities research analysts forecast that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, May 15th. Investors of record on Wednesday, April 15th will be given a $0.63 dividend. The ex-dividend date is Wednesday, April 15th. This represents a $2.52 dividend on an annualized basis and a yield of 2.3%. Abbott Laboratories’s dividend payout ratio (DPR) is currently 67.74%.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.